EUVIMEDEUVIMED entdecken
Open Access

Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis

Robert Silasi, Ravi S Keshari, Tomohiro Abe, Stephanie D Byrum, Girija Regmi, Cristina Lupu, Constantin Georgescu, Joe H Simmons, Aleksandr Shamanaev, Samantha A Moellmer, Cristina Puy, Joseph J Shatzel und 9 weitere

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.06.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Robert Silasi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. Hauptthemen laut MEDLINE: Sepsis, Factor XI, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sepsis remains a major clinical challenge characterized by dysregulated immune response, coagulation abnormalities, and multiorgan failure, leading to high morbidity and mortality. OBJECTIVES: This study investigated the therapeutic potential of abelacimab, a monoclonal antibody targeting the plasma zymogen factor (F)XI, in a new baboon model of Staphylococcus aureus sepsis. METHODS: Healthy Papio anubis baboons were randomly assigned to control or abelacimab treatment groups. Both groups (n = 6, each) were intravenously infused with a median lethal (LD50) dose of live S aureus. The treatment group was administered abelacimab 30 minutes after the onset of bacterial infusion. Hematologic, coagulation, inflammatory, and organ function parameters were monitored for 7 days or until the animal exhibited signs of irreversible organ failure. Proteomic analysis was conducted to elucidate the underlying mechanisms by which abelacimab offered protection. RESULTS: All 6 abelacimab-treated baboons survived until the 7-day endpoint, while 3 out of 6 untreated controls succumbed to sepsis within 102 hours. Abelacimab significantly attenuated sepsis-induced coagulopathy without signs of bleeding, as evidenced by biochemical tests and pathology analysis. Treated animals exhibited decreased proinflammatory cytokines, diminished neutrophil activation, and preservation of endothelial integrity, collectively conferring robust protection against organ damage. Proteomic analysis revealed that abelacimab modulated pathways related to coagulation, inflammation, and tissue injury, contributing to improved survival outcomes. CONCLUSION: FXI inhibition by abelacimab offers significant protection by attenuating activation of coagulation, reducing inflammation, and preventing organ failure. Targeting FXI may be a promising therapeutic strategy for managing sepsis by addressing multiple facets of its complex pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SepsisFactor XIStaphylococcal InfectionsStaphylococcus aureusAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnimalsDisease Models, AnimalBlood CoagulationPapio anubisPapioTime FactorsInflammation Mediators

Stichwörter der Autor:innen

Staphylococcus aureusabelacimabfactor XIproteomicssepsis

Substanzen

Factor XIAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedInflammation Mediators

Autor:innen und Institutionen

  • Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Michale E. Keeling Center for Comparative Medicine and Research, University of Texas MD Anderson Cancer Center, Bastrop, Texas, USA.
  • Anthos Therapeutics, Cambridge, Massachusetts, USA.
  • Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA.
  • Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIH HHS
  • Anthos Therapeutics
  • National Institutes of Health
  • National Science Foundation
  • National Institute of General Medical Sciences

Zitieren

APA

Silasi, R., Keshari, R. S., Abe, T., Byrum, S. D., Regmi, G., Lupu, C., Georgescu, C., Simmons, J. H., Shamanaev, A., Moellmer, S. A., Puy, C., Shatzel, J. J., Province, D., Edmondson, R. D., Mackintosh, S. G., Avaritt, N. L., Bloomfield, D., Gailani, D., Tackett, A. J., …, & Lupu, F. (2025). Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.06.018

Vancouver

Silasi R, Keshari RS, Abe T, Byrum SD, Regmi G, Lupu C, et al. Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.06.018

BibTeX
@article{Silasi2025,
  author = {Silasi, Robert and Keshari, Ravi S and Abe, Tomohiro and Byrum, Stephanie D and Regmi, Girija and Lupu, Cristina and Georgescu, Constantin and Simmons, Joe H and Shamanaev, Aleksandr and Moellmer, Samantha A and Puy, Cristina and Shatzel, Joseph J and Province, Dennis and Edmondson, Rick D and Mackintosh, Samuel G and Avaritt, Nathan L and Bloomfield, Dan and Gailani, David and Tackett, Alan J and McCarty, Owen J T and Lupu, Florea},
  title = {Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.06.018}
}
Kostenlos starten →